NBRC Pharmacology Practice Exam

Lovenox, which is the brand name for enoxaparin, is a low molecular weight heparin used primarily for the prevention and treatment of thromboembolic disorders. It is particularly effective in preventing deep vein thrombosis (DVT), which can lead to leg clots, and pulmonary embolism in patients at high risk, such as those undergoing surgery, those with limited mobility, or those with certain medical conditions.

The mechanism of action of Lovenox involves the inhibition of factor Xa and factor IIa (thrombin), which are crucial components in the coagulation cascade. By reducing the ability of the blood to clot, Lovenox effectively lowers the risk of clot formation in the legs, which is especially important during periods of immobility or following surgical procedures.

In contrast, the other listed conditions do not align with the primary indications for Lovenox. While respiratory distress could relate to complications from clots, it is not specifically the target of Lovenox. Sepsis is an infection-related condition that requires antibiotics and other supportive care, while cardiac arrest is typically a result of electrical problems in the heart or other acute cardiac issues, not directly addressed by anticoagulant therapy like Lovenox. Thus, the